Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy
(CAPECITABINE-OXALIPLATIN + BEVACIZUMAB) with Selective Radiotherapy and Chemotherapy with
CAPECITABINE Use in Patients with Intermediate-Risk Cancer of the Rectum Defined by Magnetic
Resonance Imaging.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo